Ivacaftor affects the susceptibility of standard-of-care drugs used to treat

Avneesh Shrivastava, Sanjay Singh, Gunavanthi D Boorgula, Rodolfo-Amaro Galvez, Shashikant Srivastava

Abstract read

In one paragraph

Article in Antimicrobial agents and chemotherapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Avneesh ShrivastavaDivision of Infectious Diseases, Department of Medicine, School of Medicine, University of Texas at Tyler, Tyler, Texas, USA.

Sanjay SinghDivision of Infectious Diseases, Department of Medicine, School of Medicine, University of Texas at Tyler, Tyler, Texas, USA.ORCID 0000-0003-4601-5673

Gunavanthi D BoorgulaDivision of Infectious Diseases, Department of Medicine, School of Medicine, University of Texas at Tyler, Tyler, Texas, USA.

Rodolfo-Amaro GalvezDepartment of Medicine, Section of Pulmonary and Critical Care, School of Medicine, University of Texas at Tyler, Tyler, Texas, USA.

Shashikant SrivastavaDivision of Infectious Diseases, Department of Medicine, School of Medicine, University of Texas at Tyler, Tyler, Texas, USA.ORCID 0000-0002-8786-8851

Funding

Short course combination regimens for treatment of Mycobacterium avium pulmonary disease: a translational bench-to-bedside approachR01AI179827 · NIAID · UNIVERSITY OF TEXAS HLTH CTR AT TYLER · PI Shashi Kant · 2024 to 2026

$1.7M

Cystic Fibrosis Foundation KANT23G0National Institute of Allergy and Infectious Diseases 1R01AI179827NIAID NIH HHS R01 AI179827

6 · The paper itself

Abstract

Patients with cystic fibrosis have dysfunctional cystic fibrosis transmembrane conductance regulator (CFTR), and this predisposes them to nontuberculous mycobacteria (NTM), including

Indexed as

AminophenolsAnti-Bacterial AgentsLung DiseasesMycobacterium abscessusMycobacterium Infections, NontuberculousQuinolonesAmikacinCystic FibrosisCystic Fibrosis Transmembrane Conductance RegulatorHumansImipenemMicrobial Sensitivity TestsAmikacinAminophenolsAnti-Bacterial AgentsCystic Fibrosis Transmembrane Conductance RegulatorImipenemivacaftorQuinolonesCFTR modulatorcystic fibrosisnontuberculous mycobacteriasusceptibility

Identifiers

PMID40372084

DOI10.1128/aac.00030-25

PMCPMC12135516

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.